R
Relmada Therapeutics, Inc.
RLMD · NASDAQ · Healthcare · 503M
Closing price
$3.39
+6.94% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
1.5×
Enterprise value / EBITDAEV/EBITDA
-2.3×
Free cash flow yieldFCF yield
-34.2%
Return on equityROE
-66.3%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
0.1×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.